{"id":2791,"date":"2026-08-31T11:00:00","date_gmt":"2026-08-31T15:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2791"},"modified":"2026-08-31T19:40:54","modified_gmt":"2026-08-31T23:40:54","slug":"cd73-blockade-reverses-selinexor-linked-immune-suppression","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2791","title":{"rendered":"CD73 Blockade Reverses Selinexor-Linked Immune Suppression"},"content":{"rendered":"

Institutions:<\/strong> Peking University Third Hospital \/ Antengene · Compounds:<\/strong> ATG-037 (CD73 Inhibitor) + ATG-010 (Selinexor) · Indication:<\/strong> Multiple Myeloma · Stage:<\/strong> Preclinical · Date:<\/strong> August 27, 2026<\/p>\n

\"20260831_Peking_University_Antengene_CD73_Selinexor_Technology_and_Modalities\"<\/p>\n

Summary<\/h4>\n

A peer-reviewed preclinical study from Peking University collaborators and Antengene identified CD73 upregulation as a potential adaptive immune-suppression mechanism after selinexor exposure. In a syngeneic J558 myeloma model, the ATG-037 CD73 inhibitor plus ATG-010 selinexor produced 62% tumor-growth inhibition versus 31% and 43% for the respective monotherapies. Single-cell and co-culture experiments associated the combination with CD8 T-cell activation, increased infiltration, granzyme B and interferon-gamma. The signal is mechanistically coherent but remains limited to cell lines, co-culture and one murine model, without human marrow evidence, pharmacokinetic compatibility, survival benefit or clinical safety.<\/p>\n

What Happened<\/h4>\n

Investigators first measured CD73 after selinexor treatment across tumor cell lines and found upregulation in the majority assessed. BALB\/c mice inoculated with J558 cells then received vehicle, ATG-037, ATG-010 or the combination; the combination reduced tumor growth more than either single agent. Single-cell RNA sequencing implicated CD8 activation and CD80-CD28 signaling involving Enpp1-positive cells, and immunofluorescence showed greater CD8 infiltration. In a CD8 T-cell\/myeloma co-culture, CD73 inhibition increased selinexor-associated killing and raised granzyme B and interferon-gamma. The paper does not report a patient cohort, orthogonal genetic validation in human marrow, long-term survival, normal-HSPC effects, detailed systemic toxicity or exposure-response bridging to feasible clinical doses.<\/p>\n

Deep Analysis<\/h4>\n

Selinexor-induced CD73 could convert extracellular AMP to immunosuppressive adenosine and blunt T-cell function, making CD73 blockade a rational combination, and synergy across tumor growth, immune infiltration and effector readouts supports more than a single assay artifact. CD73 has enzymatic and nonenzymatic roles, however, and the study does not prove that adenosine flux is the necessary causal link. The J558 flank model and simplified co-culture also do not recreate heavily treated human myeloma, spatial marrow niches, stromal support, T-cell exhaustion or concurrent therapy, so higher apparent combination activity may not survive exposure limits or overlapping toxicities; patient biopsies showing on-treatment CD73 induction and CD8 suppression would provide a biomarker-defined path to translation.<\/p>\n

Company and Product Background<\/h4>\n

Peking University Third Hospital investigators collaborated with Shanghai Antengene, which supplied ATG-010 (selinexor) and ATG-037 (the CD73 inhibitor) for the study. Selinexor blocks exportin-1, retaining tumor suppressors in the nucleus and altering oncogenic RNA\/protein programs; CD73, or NT5E, generates extracellular adenosine that can suppress T-cell activity through adenosine receptors. Multiple myeloma is a clonal plasma-cell malignancy centered in the bone marrow, and relapsed disease is shaped by genomic evolution, stromal signaling, immune exhaustion and treatment pressure. Selinexor is approved in combination regimens but has dose-limiting gastrointestinal, constitutional and hematologic toxicities.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Model<\/td>\nSyngeneic J558 myeloma mouse model, CD8 T-cell\/myeloma co-culture<\/td>\n<\/tr>\n
Efficacy<\/td>\n62% combination tumor-growth inhibition vs. 31% (CD73i alone), 43% (selinexor alone)<\/td>\n<\/tr>\n
Mechanism<\/td>\nCD73 upregulation post-selinexor; combination increases CD8 activation, granzyme B, IFN-gamma<\/td>\n<\/tr>\n
Validation Status<\/td>\nPeer-reviewed, but preclinical only; no human marrow or clinical data<\/td>\n<\/tr>\n
Signal Type<\/td>\nAcademic\/industry-linked combination mechanism study<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Synergy across tumor growth, immune infiltration and effector T-cell readouts in a peer-reviewed study supports a mechanistically coherent adenosine-checkpoint hypothesis that could rationalize combining CD73 blockade with a clinically used XPO1 inhibitor.<\/p>\n

Bear case:<\/strong> A single flank mouse model and simplified co-culture do not recreate human marrow biology, treatment history or overlapping toxicities, and the study does not establish that adenosine flux, rather than another CD73 function, is the causal driver of the observed effect.<\/p>\n

InSilens Take<\/h4>\n

The paper offers a credible resistance-tolerance hypothesis around a clinically used XPO1 inhibitor, but it is an early mechanism signal, not a treatment-ready combination. Its value lies in a testable biomarker, CD73 induction after selinexor, and human marrow confirmation, causal adenosine biology and clinically compatible exposure are essential before the combination can be ranked against established myeloma regimens.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 3\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> High on facts, Moderate-low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

A peer-reviewed preclinical study from Peking University collaborators and Antengene identified CD73 upregulation as a potential adaptive immune-suppression mechanism after selinexor exposure. In a syngeneic J558 myeloma model, the ATG-037 CD73 inhibitor plus ATG-010…<\/p>\n","protected":false},"author":1,"featured_media":2799,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[486,488,30,487],"class_list":["post-2791","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-antengene","tag-cd73","tag-multiple-myeloma","tag-selinexor"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2791"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2791\/revisions"}],"predecessor-version":[{"id":2807,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2791\/revisions\/2807"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2799"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}